Mowatt et al., 2010 - Google Patents
Systematic review of the clinical and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection …Mowatt et al., 2010
View PDF- Document ID
- 3124835552546001612
- Author
- Mowatt G
- Zhu S
- Kilonzo M
- Boachie C
- Fraser C
- Griffiths T
- N'Dow J
- Nabi G
- Cook J
- Vale L
- Publication year
- Publication venue
- Health technology assessment
External Links
Snippet
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic
diagnosis and urine biomarkers (FISH, Imm Page 1 Health Technology Assessment 2010; Vol.
14: No. 4 Health Technology Assessment NIHR HTA programme www.hta.ac.uk January 2010 …
- 206010005003 Bladder cancer 0 title abstract description 166
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mowatt et al. | Systematic review of the clinical and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. | |
Elta et al. | ACG clinical guideline: diagnosis and management of pancreatic cysts | |
Kassouf et al. | Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations | |
Steiner et al. | Early results of bladder‐cancer screening in a high‐risk population of heavy smokers | |
Burt et al. | Colorectal cancer screening | |
Maas et al. | Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer | |
Laudadio et al. | Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice | |
Flory et al. | Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study | |
Shiff et al. | Ultrasound verification of bladder damage is associated with known biomarkers of bladder cancer in adults chronically infected with Schistosoma haematobium in Ghana | |
Rove et al. | Systematic review of bladder cancer outcomes in patients with spina bifida | |
Zhang et al. | Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study | |
Berrettini et al. | Bladder urothelial neoplasms in pediatric age: experience at three tertiary centers | |
De Bekker‐Grob et al. | Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? | |
Quirke et al. | Histopathological work-up of resection specimens, local excisions and biopsies in colorectal cancer | |
Hashiguchi et al. | Prognostic significance of the number of lymph nodes examined in colon cancer surgery: clinical application beyond simple measurement | |
Pech et al. | Conclusions from the histological diagnosis of low-grade intraepithelial neoplasia in Barrett's oesophagus | |
Wang et al. | The prevalence and risk factors of gastric polyp in asymptomatic patients receiving health examination | |
Bhatt et al. | Recent advances in urinary bladder cancer detection | |
Chen et al. | Prognostic analysis of diagnostic ureteroscopic biopsy for intravesical recurrence of upper urinary tract urothelial carcinoma | |
Kawamura et al. | “Endoscopic” adenoma detection rate as a quality indicator of colonoscopy: First report from the J‐SCOUT study | |
Wight et al. | Improving diagnostic yield of biliary brushings cytology for pancreatic cancer and cholangiocarcinoma | |
Bresalier | Early detection of and screening for colorectal neoplasia | |
Park et al. | Diagnostic yield of advanced colorectal neoplasia at colonoscopy, according to indications: an investigation from the Korean Association for the Study of Intestinal Diseases (KASID) | |
Yamada et al. | Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy | |
Gado et al. | Improving the yield of histological sampling in patients with suspected colorectal cancer during colonoscopy by introducing a colonoscopy quality assurance program |